Visceral fat reduction decreases chronic low-grade inflammation (inflammaging), a key driver of age-related pathology ( 3.2 Growth hormone axis restoration Growth hormone (GH) secretion declines approximately 14% per decade after age 30, resulting in decreased lean body mass, increased adiposity (particularly visceral fat), reduced bone density, decreased skin thickness, and impaired recovery from illness or injury, a phenomenon termed somatopause ( CJC-1295, a long-acting GHRH analog incorporating a Drug Affinity Complex (DAC) for albumin binding, addresses somatopause by restoring more youthful GH secretion patterns ( Ipamorelin complements CJC-1295 by stimulating GH release through ghrelin receptor activation rather than GHRH pathways (Malavige et al., 2021)
Some patients report a noticeable boost in energy, focus, or mental clarity shortly after treatment, while others experience more gradual benefits with consistent weekly injections over time
doi: 10.1016/j.autrev.2020.102463 223
Keep a firm grip on the plunger before the needle goes in